AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15833501
Drug: Pentosan polysulfate
RxNorm normalized name: Pentosan polysulfate
DrugBank: Pentosan polysulfate (DB00686)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentosan polysulfate sodium (PPS) 600 mg
Trial: 15833501
Drug: Pentosan polysulfate
RxNorm normalized name: Pentosan polysulfate
DrugBank: Pentosan polysulfate (DB00686)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentosan polysulfate sodium (PPS) 900 mg
Trial: 11791087
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated estrogen 0.625 mg and medroxyprogesterone acetate 2.5 mg per day
Trial: 11791087
Drug: Reduced dose
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced dose of oral conjugated estrogen
Trial: 11791087
Drug: Calcium supplement
RxNorm normalized name: Calcium supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplement (control group)
Trial: 11791087
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy (full and reduced dose)
Trial: 10527987
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment time (standard IVF procedure)
Trial: 1066813
Drug: Chlorhexidine gel
RxNorm normalized name: chlorhexidine Oral Gel
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine gel (0.2% chlorhexidine gluconate) used 3 times a day for 6 weeks
Trial: 1066813
Drug: Chlorhexidine solution
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 99.0 g in 1 L TOPICAL SOLUTION [CHLORHEXIDINE Solution]
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine solution (various concentrations: 0.05%, 0.1%, 0.15%, 0.2%) rinsed twice a day for 7 days
Trial: 21443986
Drug: Q-500 (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Q-500 (500 mg quercetin, 125 mg vitamin C, and 5 mg niacin)
Trial: 21443986
Drug: Q-1,000 (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Q-1,000 (1,000 mg quercetin, 250 mg vitamin C, and 10 mg niacin)
Trial: 19577483
Drug: Soy group
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy group (28 g/day textured soy flour for 8 weeks)
Trial: 12860500
Drug: No pharmacologic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No pharmacologic treatment (Control)
Trial: 9583728
Drug: High pre-treatment
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High pre-treatment S-VEGF (>527 pg/ml)
Trial: 9583728
Drug: Low pre-treatment
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low pre-treatment S-VEGF (n = 17, 25% of all patients)
Trial: 2573208
Drug: Famotidine 20
RxNorm normalized name: famotidine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine 20 mg q12h
Trial: 2573208
Drug: Cimetidine 300
RxNorm normalized name: cimetidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 300 mg q6h or q12h
Trial: 31045789
Drug: Serratus plane
RxNorm normalized name: Fucus serratus extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serratus plane block (SPB) with 20 ml of 0.375% ropivacaine
Trial: 24502880
Drug: GDF-15 >1800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GDF-15 >1800 ng/L
Trial: 24502880
Drug: GDF-15 <1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GDF-15 <1200 ng/L
Trial: 22410599
Drug: Short-term life
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term life review (60 minutes, twice a week)
Trial: 20453155
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups underwent identical physical therapy training (3 sessions a week for 4 weeks)
Trial: 9461369
Drug: salbutamol (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: salbutamol (0.25 ml Ventolin 0.5%)
Trial: 9461369
Drug: ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ipratropium bromide (0.25 ml Atrovent 0.025%)
Trial: 9461369
Drug: none (routine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: none (routine administration of bronchodilators)
Trial: 2651951
Drug: Slow channel
RxNorm normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow channel calcium entry blocker (Ca antagonist)
Trial: 23127158
Drug: Localized radiofrequency
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Localized radiofrequency heat (RFH) therapy
Trial: 19523421
Drug: DHAD injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHAD injection
Trial: 8783218
Drug: Hypnotic obstruction
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypnotic obstruction of the left visual field
Trial: 8783218
Drug: Hypnotic obstruction
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypnotic obstruction of the right visual field
Trial: 8783218
Drug: Hypnotic obstruction
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypnotic obstruction
Trial: 1740583
Drug: Honeybee venom
RxNorm normalized name: bushmaster venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Honeybee venom immunotherapy (VIT)
Trial: 1740583
Drug: Yellow jacket
RxNorm normalized name: venom-yellow jacket
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yellow jacket venom immunotherapy (VIT)
Trial: 6326999
Drug: Combined radiotherapy
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined radiotherapy and chemotherapy (4200 rad)
Trial: 6326999
Drug: Combined radiotherapy
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined radiotherapy and chemotherapy (3000 rad)
Trial: 31902373
Drug: Whole raw
RxNorm normalized name: raw sugar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole raw Gala apples (approximately 200 g)
Trial: 31150780
Drug: Placebo conditioning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo conditioning with instrumental control over treatment administration
Trial: 31150780
Drug: Standard passive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard passive placebo conditioning without any control over treatment administration
Trial: 29340524
Drug: Positive control
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive control group (no treatment)
Trial: 24673044
Drug: Auricular points
RxNorm normalized name: brilliant green
DrugBank: Brilliant green cation (DB11279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Auricular points group (magnetic-ball sticking therapy)
Trial: 16633709
Drug: Corticosteroid +
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid + anesthetic agent injection
Trial: 10397617
Drug: Fast dissolving
RxNorm normalized name: Mucinex Sinus-Max Day/Night Fast Dissolving Gels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast dissolving reference formulation
Trial: 10397617
Drug: Hypothetical slow
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypothetical slow dissolving test formulation
Trial: 6353428
Drug: Oxymetazoline (0.025%)
RxNorm normalized name: Oxymethazoline
DrugBank: Oxymetazoline (DB00935)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxymetazoline (0.025%) ophthalmic solution
Trial: 6353428
Drug: Naphazoline (0.04%)
RxNorm normalized name: naphazoline 0.0004 MG/MG
DrugBank: Naphazoline (DB06711)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naphazoline (0.04%) solution
Trial: 31469749
Drug: Fractional ablative
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional ablative CO2 laser treatment
Trial: 29665830
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy plus a brief GOH-based intervention (CT-GOHT)
Trial: 16606646
Drug: Sulfasalazine (SSZ)
RxNorm normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulfasalazine (SSZ) 2 g/day
Trial: 11153633
Drug: Hypothermic group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypothermic group (n = 15), cooled to 32 to 33 degrees C after administration of vecuronium, midazolam, and buprenorphine.
Trial: 11153633
Drug: Normothermic group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normothermic group (n = 11), body temperature controlled at 36 to 37 degrees C with the same treatment as hypothermic group.
Trial: 9100038
Drug: Ketoconazole 200
RxNorm normalized name: ketoconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole 200 to 600 mg/d plus prednisone 2.5 mg/d
Trial: 23900984
Drug: Intravenous propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous propofol using intermittent bolus technique
Trial: 23900984
Drug: Intravenous propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous propofol using continuous infusion
Trial: 24336997
Drug: Mindfulness-Based Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-Based Cognitive Therapy (MBCT) program
Trial: 21050553
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of dinoprostone suppository and ethacridine
Trial: 18437172
Drug: Various compounds
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various compounds targeting MAPK pathway
Trial: 15518608
Drug: Atorvastatin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin with mibefradil
Trial: 15518608
Drug: Atorvastatin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin with itraconazole
Trial: 8354918
Drug: ranitidine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ranitidine plus amoxicillin plus metronidazole
Trial: 3490195
Drug: Propofol, 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol, 2.5 mg/kg IV for induction; 7 +/- 2 mg/min continuous infusion for maintenance
Trial: 3490195
Drug: Methohexital, 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methohexital, 1.5 mg/kg IV for induction; 6 +/- 2 mg/min continuous infusion for maintenance
Trial: 27197106
Drug: Electromyographic biofeedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electromyographic biofeedback treatment after progressive muscular relaxation training
Trial: 22854660
Drug: Quinvaxem (®)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinvaxem (®) vaccine
Trial: 22854660
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose of Quinvaxem (®)
Trial: 22854660
Drug: Quinvaxem (®)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinvaxem (®) with concomitant measles vaccine
Trial: 20488469
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose antibiotic prophylaxis
Trial: 20488469
Drug: Endoscopic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic therapy (dextranomer/hyaluronic acid copolymer)
Trial: 20488469
Drug: Surveillance group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surveillance group on antibiotic treatment only for febrile urinary tract infection
Trial: 8097280
Drug: EMD 49980
RxNorm normalized name: Emdisterone
DrugBank: Drostanolone propionate (DB14655)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMD 49980 monotherapy
Trial: 8097280
Drug: EMD 49980
RxNorm normalized name: Emdisterone
DrugBank: Drostanolone propionate (DB14655)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMD 49980 co-administered with levodopa
Trial: 2950359
Drug: VAC/FMC chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAC/FMC chemotherapy with bromoergocryptine
Trial: 2950359
Drug: VAC/FMC chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAC/FMC chemotherapy without bromoergocryptine
Trial: 2950359
Drug: VAC/FMC chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAC/FMC chemotherapy with medroxyprogesterone acetate (MAP)
Trial: 2950359
Drug: VAC/FMC chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAC/FMC chemotherapy without MAP
Trial: 27393139
Drug: Lithium carbonate
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lithium carbonate 25 mg/kg TBW/day in two daily doses
Trial: 16766279
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg hydrochlorothiazide (HCT)
Trial: 16766279
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg hydrochlorothiazide (HCT) and 5 mg amyloride
Trial: 16766279
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg hydrochlorothiazide (HCT) and 50 mg spironolactone
Trial: 15233245
Drug: Supervised outpatient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised outpatient exercise training program (3 times weekly on non-dialysis days)
Trial: 15233245
Drug: Training program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Training program with stationary bicycles during HD sessions (3 times weekly)
Trial: 9134070
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch plus four smoking cessation sessions with a nurse-practitioner (moderate-intensity condition, MI)
Trial: 9134070
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch plus four smoking cessation sessions plus 16 weekly individual cognitive/behavioral relapse-prevention therapy sessions (high-intensity condition, HI)
Trial: 3310727
Drug: Nalbuphine (NAL)
DrugBank: Nalbuphine (DB00844)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nalbuphine (NAL) 1.5 mg/kg BW
Trial: 3310727
Drug: Nalbuphine (NAL)
DrugBank: Nalbuphine (DB00844)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nalbuphine (NAL) 2.5 mg/kg BW
Trial: 3310727
Drug: Fentanyl (FE)
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl (FE) 0.005 mg/kg BW
Trial: 29344405
Drug: SLT (individualised
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SLT (individualised content, typically weekly sessions for 6-8 weeks)
Trial: 21681652
Drug: MOXI‐AF (0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOXI‐AF (0.5% moxifloxacin ophthalmic solution) dosed twice-daily for 3 days
Trial: 21681652
Drug: MOXI‐AF (0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOXI‐AF (0.5% moxifloxacin ophthalmic solution)
Trial: 17175636
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 500 ml of 50 g/L fructose daily for 3 days after escharectomy
Trial: 17175636
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of glucose 1 day after escharectomy for 3 days
Trial: 17175636
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 500 ml of 50 g/L fructose
Trial: 17175636
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of glucose
Trial: 12585341
Drug: Testosterone undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone undecanoate (TU) 20 mg daily
Trial: 9179087
Drug: Lisinopril (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (18 ± 1 mg)
Trial: 7866044
Drug: Amodiaquine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amodiaquine (30 mg/kg for 3 days)
Trial: 7866044
Drug: Chloroquine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine (30 mg/kg for 3 days)
Trial: 2475722
Drug: Cifenline (130
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cifenline (130 mg or 160 mg twice daily)
Trial: 176876
Drug: Cholestyramine (12,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholestyramine (12, 16, or 20 g daily)
Trial: 176876
Drug: Neomycin (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neomycin (1, 1.5, or 2 g daily)
Trial: 29035887
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg of Valeriana officinalis extract (valerenic acid 0.8%)
Trial: 29035887
Drug: Placebo (an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (an equal dose of vitamin E)
Trial: 24607293
Drug: melatonin 3
RxNorm normalized name: melatonin 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: melatonin 3 mg/day
Trial: 22782199
Drug: Trimethoprim-sulfamethoxazole, 480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole, 480 mg, once daily
Trial: 22782199
Drug: Lactobacillus rhamnosus
RxNorm normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus rhamnosus GR‐1 and Lactobacillus reuteri RC‐14, 109 colony-forming units, twice daily
Trial: 17239698
Drug: Ezetimibe/simvastatin 10/20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe/simvastatin 10/20 mg + fenofibrate 160 mg (EZE/SIMVA + FENO)
Trial: 12527974
Drug: 6% CHO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% CHO solution
Trial: 1561022
Drug: Placebo (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (200 mg. methylcellulose)
Trial: 31141730
Drug: Single treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single treatment of MAL DL‐PDT
Trial: 31141730
Drug: Two treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two treatments of MAL DL‐PDT (1 week apart)
Trial: 31141730
Drug: Two treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two treatments of MAL DL‐PDT
Trial: 28429904
Drug: 10 mg/d
RxNorm normalized name: Arixtra 10 mg/dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/d of lutein for 36 weeks
Trial: 21671489
Drug: rTMS (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rTMS (10 Hz, 90% motor threshold) combined with citalopram (20 mg/d)
Trial: 21671489
Drug: Sham procedure
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sham procedure combined with citalopram (20 mg/d)
Trial: 19489241
Drug: 0.1% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% ropivacaine with 0.5 microg/ml sufentanil (latent group)
Trial: 19489241
Drug: 0.15% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15% ropivacaine with 0.5 microg/ml sufentanil (active group)
Trial: 16221926
Drug: Methylphenidate (NE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (NE agonist)
Trial: 16221926
Drug: Tacrine (ACh
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrine (ACh agonist)
Trial: 16221926
Drug: Prazosin (NE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (NE antagonist)
Trial: 11518072
Drug: Haloperidol (DA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (DA antagonist)
Trial: 16221926
Drug: Biperiden (ACh
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biperiden (ACh antagonist)
Trial: 1523161
Drug: Des-glycinamide-[Arg8]vasopressin (DGAVP,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Des-glycinamide-[Arg8]vasopressin (DGAVP, 2 mg intranasal)
Trial: 1523161
Drug: Oxytocin (OXT,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytocin (OXT, 20 IU intranasal)
Trial: 28970100
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care plus three 15-minute sessions per week of one-to-one hand therapy without functional electrical stimulation.
Trial: 18378563
Drug: Fluconazole 200
RxNorm normalized name: fluconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole 200 mg for 7 days
Trial: 18378563
Drug: Fluconazole 400
RxNorm normalized name: fluconazole 400 MG in 200 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole 400 mg for 7 days
Trial: 6720317
Drug: 0.125 mg
RxNorm normalized name: digoxin 0.125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125 mg terbutaline intramuscularly
Trial: 6720317
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg terbutaline intramuscularly
Trial: 6720317
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg terbutaline intramuscularly
Trial: 6720317
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg terbutaline inhalation